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change in MPR observed for patients initiating GXR while on LA stimulants alone 
versus those on SA or SA+LA stimulants.
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Objectives: To describe patients’ characteristics and patterns of use of depot antip-
sychotics in patients with a diagnosis of schizophrenia in Germany. MethOds: 
Claims data were analysed from German patients covered by Elsevier Health Risk 
Research Database between 2009-2011 (approx 7.6 million insured persons). The 
study sample consisted of adult patients who initiated a given depot antipsychotic 
for schizophrenia (F20) or schizoaffective disorder (F25) in 2010. Baseline clinical 
characteristics of patients were searched over the year prior to depot initiation. 
Persistence (treatment duration) with depot treatment was assessed using a 
Kaplan-Meier survival analysis until discontinuation or end of the study period (31 
December 2011). Results: A total of 2,240 patients with a diagnosis of schizophre-
nia or schizoaffective disorder (mean age 50.7 years, 48.8% male) were included. At 
baseline, the main psychiatric comorbidities were major depressive disorder (38% of 
patients), substance use disorders (29%) and anxiety disorders (13%). Main somatic 
conditions were cardiovascular diseases (37%), neurological disorders (33%) and 
hyperlipidemia (27%). Depot antipsychotics prescribed were mainly risperidone 
long acting (32%), flupentixol (31%) and haloperidol decanoate (17%). Prescribers 
were psychiatrists/neurologists (58%), GPs (16%), other/unknown (26%). Median per-
sistence to depot antipsychotic treatment was 156 days. cOnclusiOns: To our 
knowledge, this is the first large database study conducted in Germany aiming at 
describing the patients’ characteristics and treatment patterns of schizophrenic 
patients treated with depot antipsychotics. It is notable that the current sub-popu-
lation of schizophrenic patients treated with depot showed substantial psychiatric 
and cardiovascular co-morbidities.
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Objectives: To visualize heterogeneity in treatment pathways and outcomes 
among children and adolescents with ADHD in Europe. MethOds: Retrospective 
chart review of 779 ADHD patients (aged 6–17 years) diagnosed by 340 clinicians 
between 2004 and 2007 in six European countries. Receipt of ADHD medication 
and/or behavioural therapy (BT) was evaluated across the study period. Patient 
characteristics, treatment patterns, physician-reported satisfaction and symp-
tom control were analysed in the total population and among patients with at 
least one switch in ADHD therapy during follow-up (switchers). Optimal treatment 
success (OTS) was defined as high satisfaction and complete symptom control 
at chart review. Results: Most patients treated with ADHD medication (89.5%) 
received methylphenidate. Among 386 patients (49.6%) who remained on their 
initial treatment throughout the chart review period, the majority (86.3%) were 
treated with ADHD medication alone or in combination with BT. Switchers (n= 393; 
50.4%) did not differ significantly at baseline from non-switchers. Few patients 
(n= 98; 12.6%) switched more than once. The most common types of switch (first 
and last treatments considered) were from one monotherapy to another (n= 91; 
23.2%) or change of medication co-administered with BT (n= 54; 13.7%). The most 
common reasons for last switch were suboptimal response (40.2%), duration of 
action (18.1%) or both (14.5%). At review, among those who switched, 11.7% discon-
tinued all ADHD treatment and 5.1% received only BT. Overall, OTS was 27.4% with 
no significant difference between switchers and non-switchers (29.1% vs 25.5%; 
p= 0.281). cOnclusiOns: About half the patients switched from their initial treat-
ment during chart review, mostly due to suboptimal response, with many (16.8%) 
discontinuing ADHD medications. Furthermore, OTS remained low regardless of 
whether a patient switched ADHD therapies. Together, these observations suggest 
currently available ADHD treatments are inadequate for achieving OTS among chil-
dren and adolescents in Europe.
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Objectives: To describe patients’ characteristics and patterns of use of depot 
antipsychotics in patients with a diagnosis of schizophrenia in Sweden. MethOds: 
A retrospective analysis was conducted based on longitudinal and population-
based data in the Swedish national health registries. The study sample con-
sisted of adult patients who initiated a treatment with any depot antipsychotic 
for schizophrenia (F20) or schizoaffective disorder (F25) in 2009-2010. Baseline 
clinical characteristics of patients were searched over the year prior to depot 
initiation. Persistence (treatment duration) with depot treatment was assessed 
using a Kaplan-Meier survival analysis until discontinuation or end of the study 
period (31 December 2011). Results: A total of 2,879 patients with a diagno-
sis of schizophrenia or schizoaffective disorder were included. Mean age was 
50.0 years and 54.4% of the patients were male. At baseline, the main psychiatric 
comorbidities were other psychotic disorders (17% of patients), substance use 
disorders (11%) and major depressive disorders (3%). Somatic conditions were 
for dementia patients, caregivers and medical professionals on the basis of a web-
based platform. MethOds: Within the PeKS, involved endusers will be provided 
disease- as well as situation-specific information from existing, evidence-based 
digital information (links, PDFs, videos) but also from local and regional informa-
tion sources. The overall aim is to enable increased knowledge and competence by 
providing situation-specific and on time information. On the other hand, the PeKS 
includes an interactive monitoring tool, thus enhancing (shared) medical decision 
support by connecting patients/caregivers and medical professionals. After the tech-
nical integration of the concept, a running prototype will be available. Results: The 
developed prototype of the ‘Personal eHealth Knowledge Space’ is realized by inte-
grating service-oriented architecture, knowledge engineering, multiagent systems, 
and wearable/portable device technologies. An interactive monitoring tool, based 
on information provided by caregivers will be realized by integrating the ‘Nurses’ 
Observation Scale for Geriatric Patients (NOSGER)’. Individualized information is 
going to be provided through push- and pull mechanisms. cOnclusiOns: Health 
support systems addressing individual dementia patients/caregiver needs have a 
large potential, however they are scarce. eHealthMonitor’s overall objective is to 
significantly increase the individualization of personal eHealth services and thereby 
the quality and patients’ acceptance of electronic health care services for preven-
tion, treatment and care. The research is funded by the European Commission, ICT 
FP7, project ID 287509.
PMH60
PsyCHoaCtiVe drUG Use, PolyPHarMaCy and Co-Morbidities in newly 
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Objectives: A number of medication surveys conducted in the U.S. have demon-
strated a high level of psychotropic drug use in patients diagnosed with pervasive 
development disorder (PDD). Medication use is of interest as not many products 
are approved for treatment in autism. Describe drug use in subjects newly diag-
nosed with PDD in Quebec province. MethOds: A cohort study was built by using 
Quebec RAMQ and Med-Echo databases for subjects having a new PDD diagnosis 
(ICD-9 codes: 299.0-299.9) between January 1998 and December 2010. Cohort entry 
date was the date of a first diagnosis confirmed by the absence of PDD diagnosis 
in previous 2 years, and aged less than 26 years. Descriptive analyses of patient 
characteristics were done at cohort entry and drug use profiles were done the 
year prior to, and within the 3 years following diagnosis. Results: A cohort of 
4684 subjects was identified; 78% of patients were male and the age ranges were 
as follows: 41.9% (1-5 years), 31.2% (6-12 years), 12.3% (13-17 years), 14.7% (18-
25 years). Prior to being diagnosed with PDD, 35% received at least 1 psychoac-
tive drug. Methylphenidate was most common in 6-12 year olds (36%) whereas 
antipsychotics were most common in the 13-17 group (28.6%) and in the adult 
population (51.7%). Antipsychotic use was also present in younger children: 5.7% 
in 1-5 year olds and 23% in 6-12 year olds, 1 year after diagnosis. Antipsychotic, 
antidepressant and anticonvulsant usage increased in the 3 years following diag-
nosis, and also with age. cOnclusiOns: Prior to PDD diagnosis, more than a third 
of the patients were on psychotropic medications, a practice that continued and 
increased after diagnosis. Psychoactive drug utilization is high and could be of 
concern if used to compensate for limited access to other treatment modalities 
such as educational and allied health therapies.
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Objectives: To assess stimulant adherence among pediatric patients with 
attention-deficit/hyperactivity disorder (ADHD) after adding guanfacine extended-
release (GXR) as adjunctive therapy to stimulants in a US managed care set-
ting. MethOds: Data from the MarketScan Commercial Claims and Encounters 
insurance claims database (2009-2011) were used. Patient inclusion criteria were: 
6-17 years old; ≥ 1 ADHD diagnosis (ICD-9-CM code 314.00 or 314.01); ≥ 1 long-acting 
(LA) and/or short-acting (SA) stimulant prescription; continued stimulant therapy 
for ≥ 30 days and ≥ 6 months of continuous insurance coverage pre- and post-
GXR initiation; and nonadherent to stimulant treatment pre-GXR. Adherence was 
assessed using the medication possession ratio [MPR] (range= 0.0-1.0), with MPR 
< 0.80 considered nonadherent. Change in stimulant adherence pre- to post-GXR 
initiation was assessed using an OLS multivariable model, adjusting for patient 
age, sex, and geographic region; GXR dose (last observed), adherence, dose sta-
bilization, and year of initiation; number of non-ADHD prescriptions pre-GXR; 
stimulant MPR pre-GXR; and stimulant received (LA, SA, SA+LA). Results: A total 
of 238 patients nonadherent to stimulants prior to initiating GXR were analyzed; 
38% were female, mean (SD) age was 10.3 (3.3) years, unadjusted pre- and post-
GXR stimulant MPR was 0.51 (0.16) and 0.82 (0.25), respectively, and the change 
in MPR was 0.31 (0.28). Among LA patients (n= 162), mean unadjusted pre-GXR 
stimulant MPR was 0.50, and 0.80 post-GXR; among SA and SA+LA patients (n= 76), 
this was 0.53 (pre-GXR) and 0.88 (post-GXR). The mean adjusted (i.e., post-model 
estimation) change in MPR was 0.29 (95% CI: 0.27-0.32) for LA patients versus 
0.34 (95% CI: 0.31-0.38) for combined SA and SA+LA patients (difference= 0.05; 
P= 0.013). cOnclusiOns: Among patients nonadherent to stimulant treatment, 
prior to initiating adjunctive GXR, adding GXR was associated with positive 
changes in stimulant adherence, with statistically significant differences in the 
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delay dependence. Few studies have explored such a relationship in Continental 
Europe. MethOds: We use data from the DEP-FR study. We ran ordered logisitic and 
heckman regressions. Results: We provide evidence: that there is a positive and 
significant correlation between cognitive, functional and behavioral declines and 
dependence on others, that an increase in dependence on others is associated with 
a decrease in informal care providers’ satisfaction, that there is a linear relationship 
between dependence on others and informal and formal care use. cOnclusiOns: 
Our results provide two main dependence policies perspectives. First, public inter-
ventions should try to reduce dependence through its three main dimensions of 
dependence on others (cognitive, behavioral and functional), and not only focus 
on the functional dimension of dependence. Second, specific measures should be 
implemented to the release of informal caregivers’ burden, which increases with 
dependence on others.
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Objectives: The prevalence and economic burden of dementia is increasing, and 
in 2007 the UK government declared dementia a national priority. This research 
aims to evaluate trends in care home costs for dementia patients following this 
announcement, and to discuss the implications for the future economic burden 
of dementia. MethOds: PubMed was searched for terms related to ‘cost’, ‘care 
homes’ and ‘dementia’. Horizon scanning was additionally performed for costs 
of care home data in the context of the wider economic burden of dementia. Only 
UK studies published after 2007 were considered, and information from a range of 
sources was assimilated to understand future implications for the economic burden 
of dementia. Results: Four relevant PubMed articles and an additional twelve 
publications from horizon scanning were identified. It was reported that two-thirds 
of care home patients have dementia and that accommodation costs represent the 
major contributor to the cost of dementia (41%). The average annual cost of a care 
room had risen from £25,953 in 2011 to £27,404 in 2012 and this was accompanied 
by a 3.9% deficit in local authority payment increases for care home residents from 
2010 to 2012. It is estimated that by 2043, more than double the current number of 
care home places will be required to match the increase in dementia prevalence, 
and the economic dependency ratio is expected to increase from 24% to 30% over 
the next 15 years. cOnclusiOns: A considerable proportion of dementia patients 
are treated in care homes and, considering the disparity between the rising costs of 
care homes and funding increases, the burden borne by patients and their families 
is increasing. There is therefore an imminent need to develop cost-effective service 
provision for dementia patients; the new remit of NICE in social care may represent 
an important step towards this.
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Objectives: Management of chronic nonmalignant pain (CNMP) is important in 
both primary care and rehabilitative medicine however, the relationships between 
CNMP and the diverse types of addiction and chemical dependency are often 
complex and clinically relevant. The objective of this pilot study was to examine 
the impact of the Functional Restoration and Pain Management (FRPM) Program 
on pain severity outcomes and controlled medication use among CNMP patients 
enrolled in the Texas Workers Compensation (TWC) benefit program. MethOds: 
A retrospective cohort analysis of administrative claims and medical records data 
was conducted among TWC chronic pain patients enrolled in the FRPM Program 
receiving buprenorphine therapy. Prescription utilization patterns and pain severity 
outcomes during a 12-month observation period were examined. Eligible patients 
were ≥ 18 years of age, continuously enrolled as TWC beneficiaries, had a history 
of utilization of chronic pain medications at enrollment, placed on buprenorphine 
therapy, and received services through the FRPM program within the observation 
period defined as date from patient entry into the program to 12 months post-
enrollment. Results: The mean age of eligible participants (N= 18) enrolled in the 
pilot study was 49.6 years ±9.5. A majority of patients were male (61%), white (61%), 
had a chronic pain lumbar diagnosis (45%), depression comorbidity (78%), and a 
substance abuse disorder (39%). Overall, patients showed a significant reduction in 
pain scores (p= 0.032) at month 12 compared to baseline. For controlled medication 
utilization, there was a significant difference in narcotic pain medication use reduc-
tion in Hispanics/Latinos (p= 0.033) compared to other racial/ethnic groups (i.e., 
Whites and African-Americans) at month 12 compared to baseline. cOnclusiOns: 
Though a pilot study, the results suggest that the FRPM program has the potential 
of improving health outcomes of patients with chronic pain, while reducing their 
use of controlled medications. A larger follow-up study is needed to validate and 
expand on these preliminary findings.
PMH70
iMPaCt of aUtisM sPeCtrUM disorders on tHe faMily – a national 
PersPeCtiVe
Vohra R., Madhavan S., Sambamoorthi U.
West Virginia University School of Pharmacy, Morgantown, WV, USA
Objectives: To examine caregiver reported impact of ASD on family as compared 
to impact of other developmental disabilities (DD) and mental health conditions 
(MHC) on family. MethOds: A cross-sectional study using 2009-2010 National 
Survey of Children with Special Health Care Needs on caregivers of children aged 
3-17 years with either ASD, DD, MHC, or both DD and MHC diagnosis (N = 18,136) 
infrequent (4% diabetes and 3% neurological disorders). The most common depot 
antipsychotics prescribed were zuclopentixol (32%), perphenazine (28%) and risp-
eridone LAI (19%). These were prescribed primarily by psychiatrists (85%). Median 
persistence to depot treatment was 195 days. cOnclusiOns: To our knowledge, 
this is the first large database study conducted in Sweden aiming at describing 
the patients’ characteristics and treatment patterns of schizophrenic patients 
treated with depot antipsychotics. It is notable that the current sub-population of 
schizophrenic patients treated with depot does not show substantial psychiatric 
and somatic co-morbidities, possibly due to under-diagnosing of co-morbidities, 
especially somatic diseases, by psychiatrists.
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Objectives: To examine the economic burden and health care utilizations of 
schizophrenia in the U.S. veteran population. MethOds: A retrospective database 
analysis was performed using the Veterans Health Administration (VHA) Medical 
SAS datasets from October 1, 2008 to September 30, 2012. Patients diagnosed with 
schizophrenia were identified using International Classification of Disease 9thRevi-
sion Clinical Modification (ICD-9-CM) diagnosis codes 295.xx, and the first diagnosis 
date was designated as the index date. A group of patients without schizophrenia 
of the same age, region, gender and index year were identified and matched by 
baseline Charlson Comorbidity Index (CCI) as the comparison group. Patients in 
both groups were required to be at least 18 years old and have continuous medical 
and pharmacy benefits 1 year pre- and 1 year post-index date. One-to-one propen-
sity score matching was used to compare health care costs and utilizations during 
the follow-up period between the schizophrenia and comparison group patients, 
adjusted for baseline demographic and clinical characteristics. Results: A total of 
171,086 eligible patients were identified for the schizophrenia and control cohorts. 
After 1:1 matching, a total of 70,045 patients were matched from each cohort with 
well-balanced baseline characteristics. Patients diagnosed with schizophrenia had 
significantly higher health care utilization in inpatient (18.12% vs. 2.30%, p< 0.01), 
emergency room (19.67% vs. 6.46%, p< 0.01), office (98.32% vs. 53.26%, p< 0.01), and 
outpatient visits (98.53% vs. 54.16%, p< 0.01). Higher health care utilizations trans-
lated into higher costs for schizophrenic patients including inpatient ($7,228 vs. 
$613, p< 0.01), pharmacy ($1,012 vs. $343, p< 0.01), outpatient ($3,998 vs. $1,302, 
p< 0.01), and total costs ($12,238 vs. $2,260, p< 0.01) relative to patients in the com-
parison group. cOnclusiOns: Schizophrenic patients were associated with a sub-
stantial economic burden compared to their matched controls.
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Objectives: To compare health care resource utilization (HRU) among schizo-
phrenic patients in the United States by the type of health insurance and estimate 
the annual expenditures. MethOds: The 2007 National Health and Interview 
Survey (NHIS) data were used for this study (150 schizophrenia cases). Multivariate 
regression was conducted to compare HRU (hospitalizations, physician visits, ER vis-
its) by type of health of insurance (any private, public only, and none). Additionally, 
2008 Medical Expenditure Panel Survey (MEPS) data were linked with the NHIS data 
(29 of the NHIS cases). Means, SE and 95% confidence intervals of prescription and 
total health care annual expenditures were calculated for schizophrenic patients 
by insurance type. Results: Multivariate analysis indicated a significant associa-
tion between the number of hospitalizations, physician visits and ER visits over 
12 months and any private insurance (β = -2.06, SE= 0.84, p= 0.01; -19.69, 8.92, 0.03; 
-22.35, 9.55, 0.02, respectively) compared to no insurance (referent). These same 
associations were not significant for the public only insurance (-0.30, 0.44, 0.16; 
-5.89, 3.91, 0.13; -7.72, 4.09, 0.06, respectively). Mean, SE [95% confidence interval] 
prescription expenditures for schizophrenic patients are similar between private 
insurance holders ($737, 215.3 [312.3-1161.6]) and those without insurance ($718, 
237.0 [249.7-1186.3]), but were higher for public insurance holders ($3781, 897.2 
[2008.1-5553.0]). Mean total health care expenditures for schizophrenic patients are 
similar between private insurance holders ($4000, 1382.4 [1273.9-6726.7]) and those 
without insurance ($4318, 2215.4 [0-8696.6]), but were higher for public insurance 
holders ($12,584, 2452.2 [7739.6-17,428.8]). cOnclusiOns: Private insurance HRU 
for schizophrenic patients is lower than public only insurance holders, followed 
by those without insurance. Seemingly contradictory, a higher expenditure among 
public insurance holders was observed. This observation could be the result of the 
more severe schizophrenic cases having only public insurance. Caution should be 
employed in the use of the expenditure calculations due to the small numbers of 
patients.
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Objectives: The increasing economic importance of dependence on others in the 
elderly population is a major problem in Europe. This problem is very concern-
ing for patients with Alzheimer’s disease, who heavily rely on informal caregivers’ 
assistance. Exploring the relationship between patients’ dependence on others 
and care expenditures is very important when planning future resources for the 
elderly and for predicting the economic consequences of interventions which may 
